CXCL1 and CXCL6 Are Potential Predictors for HCC Response to TACE
暂无分享,去创建一个
S. Bernatz | C. Döring | K. Bankov | S. Mahmoudi | F. Finkelmeier | J. Bein | F. Schulze | H. Reis | T. Vogl | L. Grünewald | P. Wild | D. Walter | A. Stehle | V. Koch | M. N. Kinzler | S. Zeuzem | Katrin Bankov
[1] J. Bruix,et al. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. , 2021, Journal of hepatology.
[2] J. Bruix,et al. Systemic treatment of hepatocellular carcinoma. An EASL position paper. , 2021, Journal of hepatology.
[3] T. Vogl,et al. Evaluation of two different transarterial chemoembolization protocols using Lipiodol and degradable starch microspheres in therapy of hepatocellular carcinoma: a prospective trial , 2021, Hepatology International.
[4] H. Goebel,et al. NanoString technology distinguishes anti‐TIF‐1γ+ from anti‐Mi‐2+ dermatomyositis patients , 2021, Brain pathology.
[5] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[6] Jhin Jieh Lim,et al. JAK/STAT signaling in hepatocellular carcinoma , 2020, Hepatic oncology.
[7] Hui Zhang,et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. , 2019, Journal of hepatology.
[8] T. de Baère,et al. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. , 2019, Cancer treatment reviews.
[9] P. Schirmacher,et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] J. Marquardt,et al. Immunotherapy of Hepatocellular Carcinoma , 2018, Oncology Research and Treatment.
[11] K. Eichler,et al. Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study , 2018, RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.
[12] M. Lucey,et al. Multidisciplinary Management of Hepatocellular Carcinoma Improves Access to Therapy and Patient Survival , 2017, Journal of clinical gastroenterology.
[13] Z. Li,et al. Elevated CXCL1 increases hepatocellular carcinoma aggressiveness and is inhibited by miRNA-200a , 2016, Oncotarget.
[14] Andrew D. Rouillard,et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..
[15] S. Ahn,et al. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial‐embolization prognostic score , 2016, Liver international : official journal of the International Association for the Study of the Liver.
[16] A. Teufel,et al. Tumor‐infiltrating, interleukin‐33–producing effector‐memory CD8+ T cells in resected hepatocellular carcinoma prolong patient survival , 2015, Hepatology.
[17] Ash A. Alizadeh,et al. Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.
[18] B. Sangro,et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] H. Heinzl,et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. , 2014, Journal of hepatology.
[20] Wenqing Tang,et al. HIF-1α Plays a Role in the Chemotactic Migration of Hepatocarcinoma Cells Through the Modulation of CXCL6 Expression , 2014, Cellular Physiology and Biochemistry.
[21] Z. Trajanoski,et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.
[22] A. Burroughs,et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] Edward Y. Chen,et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.
[24] Gaël Varoquaux,et al. Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..
[25] Kellie J. Archer,et al. High-throughput assessment of CpG site methylation for distinguishing between HCV-cirrhosis and HCV-associated hepatocellular carcinoma , 2010, Molecular Genetics and Genomics.
[26] Riccardo Lencioni,et al. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.
[27] Y. Chawla,et al. Immunology of hepatocellular carcinoma. , 1991, The Italian journal of gastroenterology.